» Articles » PMID: 34027097

Cell Therapies in the Clinic

Overview
Date 2021 May 24
PMID 34027097
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Cell therapies have emerged as a promising therapeutic modality with the potential to treat and even cure a diverse array of diseases. Cell therapies offer unique clinical and therapeutic advantages over conventional small molecules and the growing number of biologics. Particularly, living cells can simultaneously and dynamically perform complex biological functions in ways that conventional drugs cannot; cell therapies have expanded the spectrum of available therapeutic options to include key cellular functions and processes. As such, cell therapies are currently one of the most investigated therapeutic modalities in both preclinical and clinical settings, with many products having been approved and many more under active clinical investigation. Here, we highlight the diversity and key advantages of cell therapies and discuss their current clinical advances. In particular, we review 28 globally approved cell therapy products and their clinical use. We also analyze >1700 current active clinical trials of cell therapies, with an emphasis on discussing their therapeutic applications. Finally, we critically discuss the major biological, manufacturing, and regulatory challenges associated with the clinical translation of cell therapies.

Citing Articles

Activated neutrophils: A next generation cellular immunotherapy.

Kumbhojkar N, Mitragotri S Bioeng Transl Med. 2025; 10(1):e10704.

PMID: 39801751 PMC: 11711228. DOI: 10.1002/btm2.10704.


Application of Mesenchymal Stem Cell-Derived Schwann Cell-like Cells Spared Neuromuscular Junctions and Enhanced Functional Recovery After Peripheral Nerve Injury.

Nam Y, Kim J, Yum Y, Yoon J, Song H, Kim H Cells. 2025; 13(24.

PMID: 39768225 PMC: 11674609. DOI: 10.3390/cells13242137.


Engineered macrophages: an "Intelligent Repair" cellular machine for heart injury.

Zhang Z, Du H, Gao W, Zhang D Cell Regen. 2024; 13(1):25.

PMID: 39592532 PMC: 11599506. DOI: 10.1186/s13619-024-00209-7.


Biomaterials for in situ cell therapy.

Wang C, Wang S, Kang D, Dong Y BMEmat. 2024; 1(3).

PMID: 39574564 PMC: 11581612. DOI: 10.1002/bmm2.12039.


Biomaterials for Cell Manufacturing.

Miller R, Temenoff J ACS Macro Lett. 2024; 13(11):1521-1530.

PMID: 39466845 PMC: 11580378. DOI: 10.1021/acsmacrolett.4c00634.


References
1.
Kalos M, Levine B, Porter D, Katz S, Grupp S, Bagg A . T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011; 3(95):95ra73. PMC: 3393096. DOI: 10.1126/scitranslmed.3002842. View

2.
Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K . A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2020; 26(5):845-854. PMC: 8322819. DOI: 10.1016/j.bbmt.2020.01.018. View

3.
Kode J, Mukherjee S, Joglekar M, Hardikar A . Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy. 2009; 11(4):377-91. DOI: 10.1080/14653240903080367. View

4.
Gardner A, Ruffell B . Dendritic Cells and Cancer Immunity. Trends Immunol. 2016; 37(12):855-865. PMC: 5135568. DOI: 10.1016/j.it.2016.09.006. View

5.
Ruella M, Xu J, Barrett D, Fraietta J, Reich T, Ambrose D . Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018; 24(10):1499-1503. PMC: 6511988. DOI: 10.1038/s41591-018-0201-9. View